ACET
Adicet Bio Inc

3,736
Mkt Cap
$69.19M
Volume
146,303.00
52W High
$17.44
52W Low
$6.41
PE Ratio
-0.36
ACET Fundamentals
Price
$7.21
Prev Close
$7.04
Open
$6.98
50D MA
$7.67
Beta
1.03
Avg. Volume
194,134.69
EPS (Annual)
-$16.95
P/B
0.34
Rev/Employee
$0.00
$85.77
Loading...
Loading...
Poll

Earnings Recap

Adicet Bio Inc expects its $158.5 million in cash, cash equivalents, and short-term investments as of December 31, 2025, to fund operations for at least the next twelve months, with plans to meet with the FDA in Q2 2026 for prula-cel pivotal trial design.

Bullish

Adicet Bio Inc leverages a novel "off-the-shelf" gamma delta T cell platform, with lead candidate prula-cel showing clinical progress and Fast Track designation, alongside strategic prioritization of ADI-212 for mCRPC.

Bearish

Adicet Bio Inc faces significant risks from high dependence on prula-cel's regulatory approval, potential manufacturing delays due to third-party reliance, and challenges in protecting intellectual property against better-resourced competitors.

Latest ACET News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.